Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine

Treatment of Severe Hypertension During Pre-Eclampsia.A Preliminary Equivalence Study Between URAPIDIL and NICARDIPINE

The aim of this study is to confirm that URAPIDIL is as efficient and as safe as NICARDIPINE to correct severe hypertension in pre-eclamptic patients.

• efficacy endpoint : mean arterial blood pressure corrected to 105-125 mmHg after 120 min of study drug administration.
• safety endpoints : clinical, biological and ultrasound observation for any side effect.All infants will be observed in the neonatology unit (during 48h).

Inclusion criteria:

• patients 'written informed consent dated and signed by investigator and patient
• affiliation to a social security system
• single pregnancy
• arterial hypertension (PAS ≥140 and/or PAD≥90) in the context of severe pre-eclampsia

Exclusion criteria:

• patient under 18 year old or unable to give informed consent
• protocol rejected by patient-impossibility to use non invasive blood pressure monitoring
• antihypertensive treatments within 24h before inclusion
• allergy to or contraindication for one of the study drugs-pre
• eclampsia that does not require an antihypertensive treatment
• acute eclampsia-requirement for other drugs with potential dangerous interactions with study drugs
• participation to a therapeutic protocol within 6 months prior to the start of study